Menu

Daniel Gillon represents public and private companies in corporate and securities matters, including private financings, public offerings, mergers and acquisitions, SEC reporting and compliance, and corporate governance. He also advises biotechnology, pharmaceutical, and other life sciences companies on licensing and commercial agreements.

Download full bio 

Experience

  • Mirum Pharmaceuticals – $92 Million Follow-on Offering 

  • Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion 

Education

  • Duke University School of Law
    JD, cum laude, 2021

  • University of Washington
    MS, Aquatic & Fishery Sciences
    2018

  • Duke University
    BS, Biology
    with distinction, 2011


Admissions & Credentials

California